Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Fanale

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Head & Neck|June 1, 2018
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Head & Neck|April 17, 2019
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Blood|December 2, 2024
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaHun Ju Lee, Rod Ramchandren, Judah Friedman, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Head & Neck|June 1, 2018
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Plos One|March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Head & Neck|April 17, 2019
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Blood|December 2, 2024
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaHun Ju Lee, Rod Ramchandren, Judah Friedman, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomographyChelsea C Pinnix, Bouthaina Dabaja, Mohamed Amin Ahmed, et al.
Pageof 9